Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial

Trial Profile

Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial, a randomized, double blind, multicentre clinical trial

Discontinued
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2018

At a glance

  • Drugs Clopidogrel (Primary) ; Aspirin
  • Indications Stroke; Transient ischaemic attacks
  • Focus Therapeutic Use
  • Acronyms POINT
  • Most Recent Events

    • 16 May 2018 Primary endpoint of new ischemic vascular events has been met, according to results published in the New England Journal of Medicine.
    • 16 May 2018 Status changed from recruiting to discontinued, according to results published in the New England Journal of Medicine.
    • 16 May 2018 Results (n=4881) published in the New England Journal of Medicine.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top